SMAD4 loss predicts worse overall and distant metastasis‐free survival in patients with resected pancreatic adenocarcinoma

Background In select patients, pancreatic adenocarcinoma remains a local disease, yet there are no validated biomarkers to predict this behavior and who may benefit from aggressive local treatments. This study sought to determine if SMAD4 (mothers against decapentaplegic homolog 4) messenger RNA–seq...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2024-02, Vol.130 (3), p.476-484
Hauptverfasser:	Anstadt, Emily J., Carmona, Ruben, Berlin, Eva, Yegya‐Raman, Nikhil, Venigalla, Sriram, Reddy, Vishruth, Williams, Graeme R., Leibensperger, Mark R., Wojcieszynski, Andrzej, Baumann, Brian C., Lee, Major K., Plastaras, John P., Furth, Emma E., Mell, Loren K., Metz, James M., Ben‐Josef, Edgar
Format:	Artikel
Sprache:	eng
Schlagworte:	Aberration Adenocarcinoma biomarker Biomarkers Cancer Gene expression Gene sequencing Genomes genomic aberration Genomics Hazard identification Health hazards Metastases Metastasis mothers against decapentaplegic homolog 4 (SMAD4) Pancreas Pancreatic cancer Performance prediction RNA sequencing Smad4 protein Statistical models Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!